Shilpa Medicare is currently trading at Rs. 770.00, up by 5.25 points or 0.69% from its previous closing of Rs. 764.75 on the BSE.
The scrip opened at Rs. 771.80 and has touched a high and low of Rs. 777.45 and Rs. 759.60 respectively. So far 5995 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 959.95 on 18-Sep-2024 and a 52 week low of Rs. 313.55 on 10-Jan-2024.
Last one week high and low of the scrip stood at Rs. 819.85 and Rs. 759.60 respectively. The current market cap of the company is Rs. 7529.90 crore.
The promoters holding in the company stood at 44.33%, while Institutions and Non-Institutions held 17.76% and 37.90% respectively.
Shilpa Medicare has received GMP approval of Eurasia, the member countries for which are Belarus, Russia, Kazakhstan, Kyrgyzstan and Armenia, for its Unit IV located at Jadcherla, Telangana, India and Unit VII located at Nacharam, Hyderabad, Telangana, India.
Both units of Shilpa Medicare (Unit IV and Unit VII) had undergone a GMP inspection by Ministry of Health, Belarus for GMP certification from the Eurasian Economic Union in October 2024. This approval will open up significant business opportunities in these countries.
Unit IV of Shilpa Medicare is engaged in the manufacture, testing, release and distribution of sterile Injectable and non-sterile Oral finished dosage forms in the US, Europe and rest of the world markets. Unit VII of Shilpa Medicare is engaged in testing raw materials, packing materials, finished dosage forms and other testing activities.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1878.00 |
Dr. Reddys Lab | 1373.70 |
Cipla | 1537.55 |
Lupin | 2396.30 |
Zydus Lifesciences | 990.55 |
View more.. |